Nuveen, LLC Adc Therapeutics Sa Transaction History
Nuveen, LLC
- $315 Billion
- Q1 2025
A detailed history of Nuveen, LLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Nuveen, LLC holds 152,047 shares of ADCT stock, worth $215,906. This represents 0.0% of its overall portfolio holdings.
Number of Shares
152,047Holding current value
$215,906% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ADCT
# of Institutions
88Shares Held
55.2MCall Options Held
24.1KPut Options Held
44.7K-
Redmile Group, LLC San Francisco, CA15.7MShares$22.2 Million2.44% of portfolio
-
Prosight Management, LP Dallas, TX9.52MShares$13.5 Million5.62% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.97MShares$8.48 Million0.32% of portfolio
-
Morgan Stanley New York, NY3.96MShares$5.62 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$5.05 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $110M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...